Oksifrin Nazal Spray. dosed 22.5mkg / 15ml dose vials

Description

Composition
Active substance:
1 ml solution contains:
Oxymetazoline hydrochloride 11.25 mg 22.5 mg.
Excipients:
Citric acid anhydrous 25.065 g, Sodium citrate dihydrate 172.035 g, 952.425 mg Anhydrous Glycerol, Water for injections 43.839 mg 43.828 mg.
Description:
Transparent or almost transparent from nearly colorless to light yellow liquid.
Product form:
Nasal spray metered 11.25 ug / dose and 22.5 mg / dose.
10 ml (190 doses) in a bottle made of polyethylene, complete with dispensing nozzle.
10 ml (190 doses) or 15 ml (280 doses) in a vial, plastic, complete with dispensing nozzle.
1 bottle together with instructions for use in a stack of cardboard.
Contraindications
Increased sensitivity to the drug; atrophic (dry) rhinitis; closure glaucoma; state after transsphenoidal hypophysectomy; surgery on the dura (history); children up to 1 year – for Oksifrin, nasal spray metered 11.25 ug / dose; Children under the age of 6 years – to Oksifrin, nasal spray metered 22.5 ug / dose.
Carefully
In patients suffering from diseases of the cardiovascular system (hypertension, ischemic heart disease, chronic heart failure, marked atherosclerosis, tachycardia, fibrillation), disorders of carbohydrate metabolism (diabetes), impaired function of the thyroid gland (hyperthyroidism), pheochromocytoma, chronic renal failure , prostatic hyperplasia with clinical symptoms (urinary retention), increased intraocular pressure, porphyria, as well as in patients receiving inhibitors mon oaminooksidazy within the preceding 2 weeks and during 2 weeks after their withdrawal, tricyclic antidepressants, bromocriptine.
Dosage
22.5 ug / dose
Indications
Treatment of acute respiratory diseases, accompanied by rhinitis; allergic rhinitis; vasomotor rhinitis; Recovery for drainage at an inflammation of the paranasal sinuses of the nasal cavity, eustachian, otitis media; to eliminate the edema before diagnostic procedures in the nasal passages.
Interaction with other drugs
While the use of monoamine oxidase inhibitors (during the previous 2 weeks and 2 weeks after withdrawal), tricyclic antidepressants or other medications that improve blood pressure, can be observed increase in blood pressure. The drug slows down the absorption of local anesthetics, prolongs their action. Co-administration of other vasoconstrictive drugs increases the risk of side effects.
Overdose
Symptoms: anxiety, agitation, hallucinations, seizures, low body temperature, lethargy, drowsiness, coma, constriction or dilation of the pupils, fever, sweating, paleness, cyanosis, palpitations, bradycardia, arrhythmia, heart failure, high blood pressure, lowering blood pressure , nausea, vomiting, respiratory depression, respiratory arrest. Treatment: gastric lavage, administration of activated charcoal (for accidental ingestion of the drug); symptomatic.
pharmachologic effect
Pharmacological group:
Decongestant agent – alpha-agonists.
Pharmacodynamics:
It refers to the group oxymetazoline alpha agonists for topical application. It has a vasoconstrictor effect. Intranasal administration reduces swelling of the mucosa of the upper respiratory tract and nasal discharge. Restores nasal breathing. Removal of edema of nasal mucosa promotes restoration aeration nasal sinuses, middle ear cavity, which reduces the likelihood of bacterial complications (sinusitis, sinusitis, otitis media). For topical intranasal application of therapeutic concentrations, non-irritating and does not cause flushing nasal mucosa. Oxymetazoline begins to act quickly, in a matter of minutes.
The duration of action of the drug to 12 hours.
Pharmacokinetics:
For topical intranasal application oxymetazoline has no systemic action. Period oluvyvedeniya oxymetazoline when intranasal administration is 35 hours. 2.1% oxymetazoline excreted in the urine, and about 1.1% in the feces.
Pregnancy and breast-feeding
When used in pregnancy or breastfeeding should not exceed the recommended dose. The drug can be used only in cases where the potential benefit to the mother outweighs the potential risk to the fetus or child.
Conditions of supply of pharmacies
Without a prescription.
side effects
Burning or dryness of the mucous membranes of the nasal cavity, dry mouth and throat mucous membranes; sneezing; increase in secretion amount emitted from the nose; nose bleed; after a pass from the effect of the drug, the feeling of “stuffiness” of the nose (reactive hyperemia). Side effects due to systemic effects of the drug: increased blood pressure, headache, dizziness, palpitations, tachycardia, agitation, anxiety, fatigue, somnolence, sedation, irritability, sleep disturbance (in children), nausea, insomnia, rash, visual disturbances (eye), hallucinations, angioedema, pruritus, convulsions, respiratory arrest (in infants). Prolonged continuous use of vasoconstrictors may cause tachyphylaxis, atrophy of nasal mucosa and returnable edema nasal mucosa (rhinitis medicamentosa). If any of these instructions side effects are compounded or you notice any other side effects not mentioned in the instructions, tell your doctor.
special instructions
Avoid getting product in eyes.
To prevent the spread of infection it is necessary to use the drug individually.
Effects on ability to drive vehicles and mechanisms. After prolonged use of funds from rhinitis comprising oxymetazoline, at doses higher than the recommended one can not exclude the overall impact on the cardiovascular system and the central nervous system. In these cases, you should be careful when driving and busy with other potentially hazardous activities that require high concentration and psychomotor speed reactions.
Storage conditions
Store at a temperature not higher than 25 C. Keep out of reach of children.
Dosing and Administration
Intranasally.
Children aged 1 to 6 years: 1 injection Oksifrin, nasal spray metered 11.25 micrograms / dose in each nostril 2-3 times a day. The preparation is applied 5- 7 days. The drug can be administered again only a few days later. Adults and children over 6 years: 1 injection Oksifrin, nasal spray dosage of 22.5 mg / dose in each nostril 2-3 times a day. If symptoms worsen or there is no improvement within 3 days, you should consult with your doctor. At the recommended dose without consulting your doctor, do not use more than 7 days.
Doses higher than those recommended may be used only under medical supervision. With frequent and prolonged use of the drug feeling “stuffy” nose may reappear or worsen. When these symptoms should discontinue treatment and consult a doctor.
One injection of 45 .mu.l containing: -11.25 g oxymetazoline hydrochloride – for Oksifrin, nasal spray metered 11.25 ug / dose; -22.5 g oxymetazoline hydrochloride – for Oksifrin, nasal spray metered 22.5 ug / dose.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist